Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.21M
Average 0.22M
EPRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $88.9K rose 91.2% year over year, ahead of the +65.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 20.4% from the prior quarter. Over 3 fiscal years it compounded at +17.8% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +91.2% holds above the trailing-twelve-month pace of +65.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
Mixed currencies · from the cash flow
- Latest · FY2025
- 241.68K USD
- Year-over-year change
- +40.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.68K | +40.7% |
| FY2024 | 2024-12-31 | 171.72K | +46.6% |
| FY2023 | 2023-12-31 | 117.1K | — |
| FY2022 | 2022-12-31 | 147.89K | +67.7% |
| FY2021 | 2021-12-31 | 88.17K | — |
Depreciation & Amortization vs competitors
How EPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +65.0% is the highest of 9, against a peer median of +2.1%.
- Over three fiscal years its annual growth of +17.8% compares with a peer median of +18.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.32M USD | -1.1% | +23.7% | — | |
| FY2025 | €3.22M EUR | -38.0% | +23.8% | 71.9% | |
| LTM Mar 2026 | $2.42M USD | +13.1% | +32.0% | 136.2% | |
| LTM Mar 2026 | $1.88M USD | +27.6% | +10.4% | 13.0% | |
| LTM Mar 2026 | $718K USD | -3878.9% | — | — | |
| LTM Mar 2026 | $369K USD | +11.1% | +13.4% | — | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $263.36K USD | +65.0% | +17.8% | — |
| LTM Sep 2026 | $152K USD | -97.9% | — | — | |
| LTM Mar 2026 | $142.16K USD | — | — | — | |
| Peer median (excluding EPRX) | — | +2.1% | +18.7% | 42.4% | |
Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (18.18M) | (18.99M) | (21.81M) | (25.74M) | (39.22M) |
| Depreciation & Amortization | 88.17K | 147.89K | 117.1K | 171.72K | 241.68K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 1.43M | 1.06M | 3.22M | 0 |
| Change in Working Capital | (167.16K) | 1.51M | 4.03M | (6.76M) | (725.6K) |
| Accounts Receivables | 150.92K | 230.48K | (78.09K) | (101.39K) | (438.64K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.32M | 435.12K | (714.88K) | 2.4M |
| Other Working Capital | (318.07K) | (39.96K) | 3.67M | (5.95M) | (2.69M) |
| Other Non-Cash Items | 6.68M | 1.5M | 977.18K | (880.5K) | 10.68M |
| Operating Cash Flow | (11.58M) | (14.4M) | (15.62M) | (29.99M) | (29.03M) |
| Capital Expenditures | (341.28K) | (235.55K) | (55.25K) | (104.23K) | (598.77K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.12M) | (3.27M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 13.34M | 0 | 0 | 0 |
| Other Investing Activities | (3.97M) | 242 | 0 | 29.07K | 0 |
| Investing Cash Flow | (11.42M) | 9.83M | (55.25K) | (75.16K) | (598.77K) |
| Debt Repayment | 9.62M | (142.27K) | (59.81K) | (9.14M) | 0 |
| Common Stock Issued | 29.91M | 10.64M | 11.96M | 54.56M | 77.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (69.33K) | 306.77K | 3.97M | 363.06K | 0 |
| Financing Cash Flow | 39.46M | 10.8M | 15.87M | 45.78M | 77.33M |
| Effect of Forex Changes | (63.69K) | (507.4K) | 618.45K | (1.96M) | (403.1K) |
| Net Change in Cash | 16.4M | 5.73M | 811.93K | 13.76M | 47.3M |
| Free Cash Flow | (11.92M) | (14.63M) | (15.68M) | (30.1M) | (29.63M) |
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Intrinsic Alpha fair value
Locked
Current Price
$6.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.